Cercar

01/08/2024 EMPASIPRUBART (ARGX-117) IN MULTIFOCAL MOTOR NEUROPATHY: INITIAL SAFETY AND EFFICACY DATA OF THE PHASE 2 ARDA STUDY
van der Pol, WL, Peric, S, Querol, L, Hussain, Y, Cadour, S, Van de Walle, I, Persson, E, Van Hoomissen, I, Mashchenko, O, Vujcic, M, Van de Steen, O, Allen, JA. EMPASIPRUBART (ARGX-117) IN MULTIFOCAL MOTOR NEUROPATHY: INITIAL SAFETY AND EFFICACY DATA OF THE PHASE 2 ARDA STUDY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024 SERUM PROTEOME IN GUILLAIN-BARRE SYNDROME USING AN APTAMER-BASED PROTEOMICS PLATFORM
Martín-Aguilar, L, Collet, R, Lleixà, C, Caballero-Avila, M, Tejada-Illa, C, Pascual-Goñi, E, Sedano-Tous, MJ, Casasnovas, C, Gutiérrez-Gutiérrez, G, Pardo-Fernández, J, Rojas, R, Turón, J, Gallardo, E, Cortés-Vicente, E, Llansó, L, García, JM, Farrés, J, Querol, L. SERUM PROTEOME IN GUILLAIN-BARRE SYNDROME USING AN APTAMER-BASED PROTEOMICS PLATFORM. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024 CLINICAL AND IMMUNOLOGICAL RELAPSES ARE INFREQUENT IN PATIENTS WITH ANTI-CNTN1 AUTOIMMUNE NODOPATHY
Caballero-Avila, M, Martín-Aguilar, L, Pascual-Goñi, E, Tejada-Illa, C, Collet, R, Rojas-García, R, Gallardo, E, Martínez-Martínez, L, Doneddu, P, Nobile-Orazio, E, de Winter, J, Alonso-Jimenez, A, del Real, MA, Armangué, T, Delmont, E, Xuclà-Ferrarons, T, Roche, JC, Jauregui, A, González, A, Ortiz, N, Liong, HF, de Rivera, FJR, Sparasci, D, Ripellino, P, Pérez-Pérez, H, Guerrero-Sola, A, Vegezzi, E, Baars, A, Jacobs, B, Wieske, L, Eftimov, F, Lleixà, C, Querol, L. CLINICAL AND IMMUNOLOGICAL RELAPSES ARE INFREQUENT IN PATIENTS WITH ANTI-CNTN1 AUTOIMMUNE NODOPATHY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).
01/08/2024 PHASE 3 TRIAL DESIGNS EVALUATING RILIPRUBART, A C1S-COMPLEMENT INHIBITOR, IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
Lewis, RA, Allen, J, Merkies, ISJ, van Doorn, PA, Sommer, C, Wallstroem, E, Luo, XD, Alonso-Alonso, M, Atassi, N, Querol, L. PHASE 3 TRIAL DESIGNS EVALUATING RILIPRUBART, A C1S-COMPLEMENT INHIBITOR, IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).